CRDF Stock Overview
A clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
Cardiff Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.45 |
| 52 Week High | US$6.42 |
| 52 Week Low | US$1.15 |
| Beta | 1.93 |
| 11 Month Change | -13.43% |
| 3 Month Change | 4.70% |
| 1 Year Change | 107.63% |
| 33 Year Change | -54.63% |
| 5 Year Change | 73.76% |
| Change since IPO | -99.85% |
Recent News & Updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04Recent updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Shareholder Returns
| CRDF | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | 2.5% | 2.2% |
| 1Y | 107.6% | 16.1% | 31.6% |
Return vs Industry: CRDF exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: CRDF exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| CRDF volatility | |
|---|---|
| CRDF Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRDF's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRDF's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Mark Erlander | www.cardiffoncology.com |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers.
Cardiff Oncology, Inc. Fundamentals Summary
| CRDF fundamental statistics | |
|---|---|
| Market cap | US$125.28m |
| Earnings (TTM) | -US$43.00m |
| Revenue (TTM) | US$688.00k |
182.1x
P/S Ratio-2.9x
P/E RatioIs CRDF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRDF income statement (TTM) | |
|---|---|
| Revenue | US$688.00k |
| Cost of Revenue | US$34.90m |
| Gross Profit | -US$34.21m |
| Other Expenses | US$8.79m |
| Earnings | -US$43.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | -4,973.11% |
| Net Profit Margin | -6,250.73% |
| Debt/Equity Ratio | 0% |
How did CRDF perform over the long term?
See historical performance and comparison